297
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Pilot Study of Multi-Gene Pharmacogenetic Testing for Pain Management in Oncology Palliative Medicine

ORCID Icon, , , , , , , , , & show all
Pages 737-748 | Received 15 Mar 2021, Accepted 30 Jun 2021, Published online: 20 Aug 2021

References

  • Scarborough BM , SmithCB. Optimal pain management for patients with cancer in the modern era. CA Cancer J. Clin.68, 182–196 (2018).
  • van den Beuken-van Everdingen MH , de RijkeJM , KesselsAGet al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann. Oncol.18, 1437–1449 (2007).
  • Efficace F , BottomleyA , SmitEFet al. Is a patient’s self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann. Oncol.17, 1698–1704 (2006).
  • Quinten C , CoensC , MauerMet al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet. Oncol.10, 865–871 (2009).
  • Zaza C , BaineN. Cancer pain and psychosocial factors: a critical review of the literature. J. Pain Symptom Manage.24, 526–542 (2002).
  • Zhao F , ChangVT , CleelandCet al. Determinants of pain severity changes in ambulatory patients with cancer: an analysis from Eastern Cooperative Oncology Group trial E2Z02. J. Clin. Oncol.32, 312–319 (2014).
  • Temel JS , GreerJA , El-JawahriAet al. Effects of early integrated palliative care in patients with lung and GI cancer: a randomized clinical trial. J. Clin. Oncol.7(35), 834–841 (2017).
  • Temel JS , GreerJA , MuzikanskyAet al. Early palliative care for patients with metastatic non-small-cell lung cancer. N. Engl. J. Med.363, 733–742 (2010).
  • Patel JN , WiebeLA , DunnenbergerHM , McLeodHL. Value of supportive care pharmacogenomics in oncology practice. Oncologist23, 956–964 (2018).
  • Crews KR , GaedigkA , DunnenbergerHMet al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clin. Pharmacol. Ther. doi:10.1002/cpt.2149 (2021) ( Epub ahead of print).
  • Owusu Obeng A , HamadehI , SmithM. Review of opioid pharmacogenetics and considerations for pain management. Pharmacotherapy37, 1105–1121 (2017).
  • Relling MV , KleinTE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther.89, 464–467 (2011).
  • Bruera E , KuehnN , MillerMJ , SelmserP , MacmillanK. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J. Palliative. Care.7(2), 6–9 (1990).
  • Chang VT , HwangSS , FeuermanM. Validation of the edmonton symptom assessment scale. Cancer88(9), 2164–2171 (2000).
  • Patel JN , HamadehIS. Pharmacogenomics-guided opioid management. BMJ. Support. Palliat. Care.10(4), 374–378 (2020).
  • Smith DM , WeitzelKW , ElseyARet al. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. Genet. Med.21(8), 1842–1850 (2019).
  • Elens L , van GelderT , HesselinkDA , HaufroidV , van SchaikRH. CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics14, 47–62 (2013).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.